Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis

References

• Kuziel GA, Rakoff-Nahoum S. The gut microbiome. Curr Biol. 2022;32(6):R257–33. doi:10.1016/j.cub.2022.02.023.
   PubMed Web of Science ®Google Scholar
• Zheng L, Wen XL, Duan SL. Role of metabolites derived from gut microbiota in inflammatory bowel diseasea. World J Clin Cases. 2022;10(9):2660–2677. doi:10.12998/wjcc.v10.i9.2660.
   PubMed Web of Science ®Google Scholar
• Kriaa A, Mariaule V, Jablaoui A, Rhimi S, Mkaouar H, Hernandez J, Korkmaz B, Lesner A, Maguin E, Aghdassi A. et al. Bile acids: key players in inflammatory bowel diseases? Cells. 2022;11(5):901. doi:10.3390/cells11050901.
   PubMed Web of Science ®Google Scholar
• Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer. 2022;22(12):703–722. doi:10.1038/s41568-022-00513-x.
   PubMed Web of Science ®Google Scholar
• Chen B, Bai Y, Tong F, Yan J, Zhang R, Zhong Y, Tan H, Ma X. Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes. Gut Microbes. 2023;15(1):2192155. doi:10.1080/19490976.2023.2192155.
   PubMed Web of Science ®Google Scholar
• Wahlström A, Sayin Sama I, Marschall H-U, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, Wilson DC, Cameron F, Henderson P, Kotze PG. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162(4):1147–1159.e1144. doi:10.1053/j.gastro.2021.12.282.
   PubMed Web of Science ®Google Scholar
• Varga A, Kocsis B, Sipos D, Kasa P, Vigvari S, Pal S, Dembrovszky F, Farkas K, Peterfi Z. How to apply FMT more effectively, conveniently and flexible - a comparison of FMT methods. Front Cell Infect Microbiol. 2021;11:657320. doi:10.3389/fcimb.2021.657320.
   PubMed Web of Science ®Google Scholar
• Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe. 2022;30(3):289–300. doi:10.1016/j.chom.2022.02.004.
   PubMed Web of Science ®Google Scholar
• Axelson M, Ellis E, Mork B, Garmark K, Abrahamsson A, Bjorkhem I, Ericzon BG, Einarsson C. Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid. Hepatology. 2000;31(6):1305–1312. doi:10.1053/jhep.2000.7877.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Costantino G, Camaioni E, Sadeghpour BM, Entrena A, Willson TM, Fiorucci S, Clerici C, Gioiello A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004;47(18):4559–4569. doi:10.1021/jm049904b.
   PubMed Web of Science ®Google Scholar
• Wang LX, Frey MR, Kohli R. The role of FGF19 and MALRD1 in enterohepatic bile acid signaling. Front Endocrinol. 2022;12:799648. doi:10.3389/fendo.2021.799648.
   PubMed Web of Science ®Google Scholar
• Stellaard F, Lütjohann D. Dynamics of the enterohepatic circulation of bile acids in healthy humans. Am J Physiol-Gastr L. 2021;321(1):G55–G66. doi:10.1152/ajpgi.00476.2020.
   PubMed Web of Science ®Google Scholar
• Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Monma T, Ueda H, Mizuno S, Sugiyama F, Takahashi S. et al. Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition. J Lipid Res. 2020;61(1):54–69. doi:10.1194/jlr.RA119000395.
   PubMed Web of Science ®Google Scholar
• Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res. 2012;53(10):2231–2241. doi:10.1194/jlr.D028803.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259. doi:10.1194/jlr.R500013-JLR200.
   PubMed Web of Science ®Google Scholar
• Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15(7):804?816. doi:10.3748/wjg.15.804.
   PubMed Web of Science ®Google Scholar
• Keitel V, Stindt J, Haussinger D. Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors. Handb Exp Pharmacol. 2019;256:19–49. doi:10.1007/164_2019_230.
   PubMedGoogle Scholar
• Percyrobb IW, Collee JG. Bile acids: a pH dependent antibacterial system in the gut? Br Med J. 1972;3(5830):813–815. doi:10.1136/bmj.3.5830.813.
   PubMedGoogle Scholar
• Sannasiddappa TH, Lund PA, Clarke SR. In vitro antibacterial activity of unconjugated and conjugated bile salts on staphylococcus aureus. Front Microbiol. 2017;8:1581. doi:10.3389/fmicb.2017.01581.
   PubMed Web of Science ®Google Scholar
• Dobson TE, Maxwell AR, Ramsubhag A. Antimicrobial cholic acid derivatives from the Pitch Lake bacterium Bacillus amyloliquefaciens UWI-W23. Steroids. 2018;135:50–53. doi:10.1016/j.steroids.2018.04.008.
   PubMed Web of Science ®Google Scholar
• Do Nascimento PG, Lemos TL, Almeida MC, de Souza JM, Bizerra AM, Santiago GM, da Costa JG, Coutinho HD. Lithocholic acid and derivatives: Antibacterial activity. Steroids. 2015;104:8–15. doi:10.1016/j.steroids.2015.07.007.
   PubMed Web of Science ®Google Scholar
• Thao TDH, Ryu HC, Yoo SH, Rhee DK. Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis. Biochem Pharmacol. 2008;75(11):2135–2146. doi:10.1016/j.bcp.2008.03.008.
   PubMed Web of Science ®Google Scholar
• Friedman ES, Li Y, Shen TCD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao CY. et al. FXR-Dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid. Gastroenterology. 2018;155(6):1741–1752.e1745. doi:10.1053/j.gastro.2018.08.022.
   PubMed Web of Science ®Google Scholar
• Larabi AB, Masson HLP, Bäumler AJ. Bile acids as modulators of gut microbiota composition and function. Gut Microbes. 2023;15(1):2172671. doi:10.1080/19490976.2023.2172671.
   PubMed Web of Science ®Google Scholar
• Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S, Kearney SM, Suda W, Takeshita K, Sasaki T, Okamoto S. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 2021;599(7885):458–464. doi:10.1038/s41586-021-03832-5.
   PubMed Web of Science ®Google Scholar
• Kastl A, Zong WJ, Gershuni VM, Friedman ES, Tanes C, Boateng A, Mitchell WJ, O’Connor K, Bittinger K, Terry NA. et al. Dietary fiber-based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human disease. Gut Microbes. 2022;14(1):2083417. doi:10.1080/19490976.2022.2083417.
   PubMed Web of Science ®Google Scholar
• Adhikari AA, Seegar TCM, Ficarro SB, McCurry MD, Ramachandran D, Yao LN, Chaudhari SN, Ndousse-Fetter S, Banks AS, Marto JA. et al. Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nat Chem Biol. 2020;16(3):318–326. doi:10.1038/s41589-020-0467-3.
   PubMed Web of Science ®Google Scholar
• Xu FZ, Guo FF, Hu XJ, Lin J. Crystal structure of bile salt hydrolase from Lactobacillus salivarius. Acta Crystallogr Sec F, Struc Biol Commun. 2016;72:376–381. doi:10.1107/S2053230X16005707.
   PubMed Web of Science ®Google Scholar
• Kumar RS, Brannigan JA, Prabhune AA, Pundle AV, Dodson GG, Dodson EJ, Suresh CG. Structural and functional analysis of a conjugated bile salt hydrolase from Bifidobacterium longum reveals an evolutionary relationship with penicillin V acylase. J Biol Chem. 2006;281(43):32516–32525. doi:10.1074/jbc.M604172200.
   PubMed Web of Science ®Google Scholar
• Rossocha M, Schultz-Heienbrok R, von Moeller H, Coleman JP, Saenger W. Conjugated bile acid hydrolase is a tetrameric N-terminal thiol hydrolase with specific recognition of its cholyl but not of its tauryl product. Biochemistry. 2005;44(15):5739–5748. doi:10.1021/bi0473206.
   PubMed Web of Science ®Google Scholar
• Madej T, Lanczycki CJ, Zhang D, Thiessen PA, Geer RC, Marchler-Bauer A, Bryant SH. MMDB and VAST+: tracking structural similarities between macromolecular complexes. Nucleic Acids Res. 2014;42(D1):D297–D303. doi:10.1093/nar/gkt1208.
   PubMed Web of Science ®Google Scholar
• Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA. 2008;105(36):13580–13585. doi:10.1073/pnas.0804437105.
   PubMed Web of Science ®Google Scholar
• Bi J, Fang F, Lu S, Du G, Chen J. New insight into the catalytic properties of bile salt hydrolase. J Mol Catal B Enzym. 2013;96:46–51. doi:10.1016/j.molcatb.2013.06.010.
   Google Scholar
• Song ZW, Cai YY, Lao XZ, Wang X, Lin XX, Cui YY, Kalavagunta PK, Liao J, Jin L, Shang J. et al. Taxonomic profiling and populational patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome. Microbiome. 2019;7(1):9. doi:10.1186/s40168-019-0628-3.
   PubMed Web of Science ®Google Scholar
• Coleman JP, Hudson LL. Cloning and characterization of a conjugated bile acid hydrolase gene from Clostridium perfringens. Appl Environ Microb. 1995;61(7):2514–2520. doi:10.1128/AEM.61.7.2514-2520.1995.
   PubMed Web of Science ®Google Scholar
• Elkins CA, Moser SA, Savage DC. Genes encoding bile salt hydrolases and conjugated bile salt transporters in Lactobacillus johnsonii 100-100 and other Lactobacillus species. Microbiology. 2001;147:3403–3412. doi:10.1099/00221287-147-12-3403.
   PubMed Web of Science ®Google Scholar
• Dussurget O, Cabanes D, Dehoux P, Lecuit M, Buchrieser C, Glaser P, Cossart P. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol Microbiol. 2002;45(4):1095–1106. doi:10.1046/j.1365-2958.2002.03080.x.
   PubMed Web of Science ®Google Scholar
• Delpino MV, Marchesini MI, Estein SM, Comerci DJ, Cassataro J, Fossati CA, Baldi PC. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect Immun. 2007;75(1):299–305. doi:10.1128/IAI.00952-06.
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Horibe I, Uchida K. Purification and characterization of a new hydrolase for conjugated bile acids, chenodeoxycholyltaurine hydrolase, from bacteroides vulgatus. J Biochem. 1989;106(6):1049–1053. doi:10.1093/oxfordjournals.jbchem.a122962.
   PubMed Web of Science ®Google Scholar
• Dean M, Cervellati C, Casanova E, Squerzanti M, Lanzara V, Medici A, de Laureto PP, Bergamini CM. Characterization of cholylglycine hydrolase from a bile-adapted strain of Xanthomonas maltophilia and its application for quantitative hydrolysis of conjugated bile salts. Appl Environ Microbiol. 2002;68(6):3126–3128. doi:10.1128/AEM.68.6.3126-3128.2002.
   PubMed Web of Science ®Google Scholar
• Kim GB, Yi SH, Lee BH. Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains. J Dairy Sci. 2004;87(2):258–266. doi:10.3168/jds.S0022-0302(04)73164-1.
   PubMed Web of Science ®Google Scholar
• Wells JE, Hylemon PB. Identification and characterization of a bile acid 7alpha-dehydroxylation operon in Clostridium sp. strain TO-931, a highly active 7alpha-dehydroxylating strain isolated from human feces. Appl Environ Microb. 2000;66(3):1107–1113. doi:10.1128/aem.66.3.1107-1113.2000.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Kang D-J, Hylemon PB. Isolation and characterization of a bile acid inducible 7alpha-dehydroxylating operon in Clostridium hylemonae TN271. Anaerobe. 2010;16(2):137–146. doi:10.1016/j.anaerobe.2009.05.004.
   PubMed Web of Science ®Google Scholar
• Kitahara M, Takamine F, Imamura T, Benno Y. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov. isolated from human faeces. Int J Syst Evol Microbiol. 2000;50(3):971–978. doi:10.1099/00207713-50-3-971.
   PubMedGoogle Scholar
• Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39. doi:10.1080/19490976.2015.1127483.
   PubMed Web of Science ®Google Scholar
• Grimm C, Maser E, Möbus E, Klebe G, Reuter K, Ficner R. The crystal structure of 3alpha -hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni shows a novel oligomerization pattern within the short chain dehydrogenase/reductase family. J Biol Chem. 2000;275(52):41333–41339. doi:10.1074/jbc.M007559200.
   PubMed Web of Science ®Google Scholar
• Couture J-F, Pereira De Jésus-Tran K, Roy A-M, Cantin L, Côté P-L, Legrand P, Luu-The V, Labrie F, Breton R. Comparison of crystal structures of human type 3 3α-hydroxysteroid dehydrogenase reveals an “induced-fit” mechanism and a conserved basic motif involved in the binding of androgen. Protein Sci. 2005;14(6):1485–1497. doi:10.1110/ps.051353205.
   PubMed Web of Science ®Google Scholar
• Nahoum V, Gangloff A, Legrand P, Zhu D-W, Cantin L, Zhorov BS, Luu-The V, Labrie F, Breton R, Lin S-X. Structure of the human 3α-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-Å resolution. J Biol Chem. 2001;276(45):42091–42098. doi:10.1074/jbc.M105610200.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Oda M, Kataoka S, Ueda S, Uchiyama S, Yoshida T, Kobayashi Y, Ohkubo T. Apo- and holo-structures of 3alpha-hydroxysteroid dehydrogenase from Pseudomonas sp. B-0831. Loop-helix transition induced by coenzyme binding. J Biol Chem. 2006;281(42):31876–31884. doi:10.1016/S0021-9258(19)84102-9.
   PubMed Web of Science ®Google Scholar
• Hoog SS, Pawlowski JE, Alzari PM, Penning TM, Lewis M. Three-dimensional structure of rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase: a member of the aldo-keto reductase superfamily. Proc Natl Acad Sci USA. 1994;91(7):2517–2521. doi:10.1073/pnas.91.7.2517.
   PubMed Web of Science ®Google Scholar
• Zhang B, Hu X-J, Wang X-Q, Thériault J-F, Zhu D-W, Shang P, Labrie F, Lin S-X. Human 3α-hydroxysteroid dehydrogenase type 3: structural clues of 5α-DHT reverse binding and enzyme down-regulation decreasing MCF7 cell growth. Biochem J. 2016;473(8):1037–1046. doi:10.1042/BCJ20160083.
   PubMedGoogle Scholar
• Jin Y, Stayrook SE, Albert RH, Palackal NT, Penning TM, Lewis M. Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. Biochemistry. 2001;40(34):10161–10168. doi:10.1021/bi010919a.
   PubMed Web of Science ®Google Scholar
• Chen M, Drury JE, Christianson DW, Penning TM. Conversion of human steroid 5β-reductase (AKR1D1) into 3β-hydroxysteroid dehydrogenase by single point mutation E120H: example of perfect enzyme engineering. J Biol Chem. 2012;287(20):16609–16622. doi:10.1074/jbc.M111.338780.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Nonaka T, Tanabe T, Yoshimoto T, Tsuru D, Mitsui Y. Crystal structures of the binary and ternary complexes of 7 alpha-hydroxysteroid dehydrogenase from Escherichia coli. Biochemistry. 1996;35(24):7715–7730. doi:10.1021/bi951904d.
   PubMed Web of Science ®Google Scholar
• Lou D, Wang B, Tan J, Zhu L, Cen X, Ji Q, Wang Y. The three-dimensional structure of Clostridium absonum 7α-hydroxysteroid dehydrogenase: new insights into the conserved arginines for NADP(H) recognition. Sci Rep. 2016;6(1):22885. doi:10.1038/srep22885.
   PubMedGoogle Scholar
• Kim K-H, Lee CW, Pardhe BD, Hwang J, Do H, Lee YM, Lee JH, Oh T-J. Crystal structure of an apo 7α-hydroxysteroid dehydrogenase reveals key structural changes induced by substrate and co-factor binding. J Steroid Biochem Mol Biol. 2021;212:105945. doi:10.1016/j.jsbmb.2021.105945.
   PubMed Web of Science ®Google Scholar
• Wang R, Wu J, Jin DK, Chen Y, Lv Z, Chen Q, Miao Q, Huo X, Wang F. Structure of NADP+-bound 7β-hydroxysteroid dehydrogenase reveals two cofactor-binding modes. Acta Crystallogr Sec F. 2017;73(5):246–252. doi:10.1107/S2053230X17004460.
   Google Scholar
• Savino S, Ferrandi EE, Forneris F, Rovida S, Riva S, Monti D, Mattevi A. Structural and biochemical insights into 7β-hydroxysteroid dehydrogenase stereoselectivity. Proteins Struct Funct Bioinf. 2016;84(6):859–865. doi:10.1002/prot.25036.
   PubMed Web of Science ®Google Scholar
• Doden H, Sallam Lina A, Devendran S, Ly L, Doden G, Daniel Steven L, Alves João MP, Ridlon Jason M, Müller V. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-Dehydroxylating human gut bacteria. Appl Environ Microb. 2018;84(10):e00235?00218. doi:10.1128/AEM.00235-18.
   Web of Science ®Google Scholar
• Doden HL, Wolf PG, Gaskins HR, Anantharaman K, Alves JMP, Ridlon JM. Completion of the gut microbial epi-bile acid pathway. Gut Microbes. 2021;13(1):1907271. doi:10.1080/19490976.2021.1907271.
   PubMed Web of Science ®Google Scholar
• Lee JW, Cowley ES, Wolf PG, Doden HL, Murai T, Caicedo KYO, Ly LK, Sun F, Takei H, Nittono H. et al. Formation of secondary allo-bile acids by novel enzymes from gut Firmicutes. Gut Microbes. 2022;14(1):2132903. doi:10.1080/19490976.2022.2132903.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhuang Q, Sun B, Lv W, Wang S, Xiao Q, Pang B, Zhou Y, Wang F, Chi P. et al. Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. Nat Commun. 2021;12(1):449. doi:10.1038/s41467-020-20675-2.
   PubMed Web of Science ®Google Scholar
• Faucher F, Cantin L, Luu-The V, Labrie F, Breton R. Crystal structures of human Δ4-3-ketosteroid 5β-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry. 2008;47(51):13537–13546. doi:10.1021/bi801276h.
   PubMed Web of Science ®Google Scholar
• Drury JE, Di Costanzo L, Penning TM, Christianson DW. Inhibition of human steroid 5β-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J Biol Chem. 2009;284(30):19786–19790. doi:10.1074/jbc.C109.016931.
   PubMed Web of Science ®Google Scholar
• Di Costanzo L, Drury JE, Christianson DW, Penning TM. Structure and catalytic mechanism of human steroid 5beta-reductase (AKR1D1). Mol Cell Endocrinol. 2009;301(1–2):191–198. doi:10.1016/j.mce.2008.09.013.
   PubMed Web of Science ®Google Scholar
• Di Costanzo L, Drury JE, Penning TM, Christianson DW. Crystal structure of human liver Δ4-3-ketosteroid 5β-reductase (AKR1D1) and implications for substrate binding and catalysis. J Biol Chem. 2008;283(24):16830–16839. doi:10.1074/jbc.M801778200.
   PubMed Web of Science ®Google Scholar
• Edenharder R, Hammann R. Deoxycholic acid methyl ester — a novel bacterial metabolite of cholic acid. Syst Appl Microbiol. 1985;6(1):18–22. doi:10.1016/S0723-2020(85)80005-9.
   Web of Science ®Google Scholar
• Tazuke Y, Matsuda K, Adachi K, Tsukada Y. Purification and properties of a novel sulfatase from Pseudomonas testosteroni that hydrolyzed 3 beta-hydroxy-5-cholenoic acid 3-sulfate. Biosci Biotechnol Biochem. 1998;62(9):1739–1744. doi:10.1271/bbb.62.1739.
   PubMed Web of Science ®Google Scholar
• Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK. et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123–129. doi:10.1038/s41586-020-2047-9.
   PubMed Web of Science ®Google Scholar
• Lucas LN, Barrett K, Kerby RL, Zhang Q, Cattaneo LE, Stevenson D, Rey FE, Amador-Noguez D, Manichanh C. Dominant bacterial phyla from the human gut show widespread ability to transform and conjugate bile acids. mSystems. 2021;6(4):e0080521. doi:10.1128/mSystems.00805-21.
   Web of Science ®Google Scholar
• Huijghebaert SM, Hofmann AF. Influence of the amino acid moiety on deconjugation of bile acid amidates by cholylglycine hydrolase or human fecal cultures. J Lipid Res. 1988;27(7):742–752. doi:10.1016/S0022-2275(20)38791-5.
   Web of Science ®Google Scholar
• Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature. 2020;582(7813):566–570. doi:10.1038/s41586-020-2396-4.
   PubMed Web of Science ®Google Scholar
• Jin WB, Li TT, Huo D, Qu SP, Li XV, Arifuzzaman M, Lima SF, Shi HQ, Wang AL, Putzel GG. et al. Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome. Cell. 2022;185(3):547–562.e22. doi:10.1016/j.cell.2021.12.035.
   PubMed Web of Science ®Google Scholar
• Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 2015;11(9):685–690. doi:10.1038/NCHEMBIO.1864.
   PubMed Web of Science ®Google Scholar
• Harris SC, Devendran S, Méndez-García C, Mythen SM, Wright CL, Fields CJ, Hernandez AG, Cann I, Hylemon PB, Ridlon JM. Bile acid oxidation by Eggerthella lenta strains C592 and DSM 2243T. Gut Microbes. 2018;9(6):523–539. doi:10.1080/19490976.2018.1458180.
   PubMed Web of Science ®Google Scholar
• Berr F, Kullak-Ublick GA, Paumgartner G, Munzing W, Hylemon PB. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology. 1996;111(6):1611–1620. doi:10.1016/S0016-5085(96)70024-0.
   PubMed Web of Science ®Google Scholar
• Joint Center for Structural Genomics. RCSB PDB - 4LEH: crystal structure of a bile-acid 7-alpha dehydratase (CLOSCI_03134) from Clostridium scindens ATCC 35704 at 2.90 a resolution. 2013.
   Google Scholar
• Joint Center for Structural Genomics. RCSB PDB - 4L8O: crystal structure of a bile-acid 7-alpha dehydratase (CLOHYLEM_06634) from Clostridium hylemonae DSM 15053 at 2.20 a resolution. 2013.
   Google Scholar
• Joint Center for Structural Genomics. RCSB PDB - 4N3V: crystal structure of a bile-acid 7-alpha dehydratase (CLOHIR_00079) from Clostridium hiranonis DSM 13275 at 1.89 a resolution with product added. 2013.
   Google Scholar
• Joint Center for Structural Genomics (JCSG). PDB - 4L8P: crystal structure of a bile-acid 7-alpha dehydratase (CLOHIR_00079) from Clostridium hiranonis DSM 13275 at 1.60 a resolution. 2013.
   Google Scholar
• Bhowmik S, Chiu HP, Jones DH, Chiu HJ, Miller MD, Xu QP, Farr CL, Ridlon JM, Wells JE, Elsliger MA. et al. Structure and functional characterization of a bile acid 7 alpha dehydratase BaiE in secondary bile acid synthesis. Proteins. 2016;84(3):316–331. doi:10.1002/prot.24971.
   PubMed Web of Science ®Google Scholar
• Mallonee DH, Adams JL, Hylemon PB. The bile acid-inducible baiB gene from Eubacterium sp. strain VPI 12708 encodes a bile acid-coenzyme a ligase. J Bacteriol. 1992;174(7):2065–2071. doi:10.1128/jb.174.7.2065-2071.1992.
   PubMed Web of Science ®Google Scholar
• Dawson JA, Mallonee DH, Björkhem I, Hylemon PB. Expression and characterization of a C24 bile acid 7 alpha-dehydratase from Eubacterium sp. strain VPI 12708 in Escherichia coli. J Lipid Res. 1996;37(6):1258–1267. doi:10.1016/S0022-2275(20)39155-0.
   PubMed Web of Science ®Google Scholar
• Bhowmik S, Jones DH, Chiu HP, Park IH, Chiu HJ, Axelrod HL, Farr CL, Tien HJ, Agarwalla S, Lesley SA. Structural and functional characterization of BaiA, an enzyme involved in secondary bile acid synthesis in human gut microbe. Proteins. 2014;82(2):216–229. doi:10.1002/prot.24353.
   PubMed Web of Science ®Google Scholar
• Mallonee DH, Lijewski MA, Hylemon PB. Expression in Escherichia coli and characterization of a bile acid-inducible 3 alpha-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708. Curr Microbiol. 1995;30(5):259–263. doi:10.1007/BF00295498.
   PubMed Web of Science ®Google Scholar
• Kang DJ, Ridlon JM, Moore DR, Barnes S, Hylemon PB. Clostridium scindens baiCD and baiH genes encode stereo-specific 7 alpha/7 beta-hydroxy-3-oxo-Delta(4)-cholenoic acid oxidoreductases. Biochim Biophys Acta. 2008;1781(1–2):16–25. doi:10.1016/j.bbalip.2007.10.008.
   PubMed Web of Science ®Google Scholar
• Ye HQ, Mallonee DH, Wells JE, Björkhem I, Hylemon PB. The bile acid-inducible baiF gene from Eubacterium sp. strain VPI 12708 encodes a bile acid-coenzyme a hydrolase. J Lipid Res. 1999;40(1):17–23. doi:10.1016/S0022-2275(20)33335-6.
   PubMed Web of Science ®Google Scholar
• Harris SC, Devendran S, Alves JMP, Mythen SM, Hylemon PB, Ridlon JM. Identification of a gene encoding a flavoprotein involved in bile acid metabolism by the human gut bacterium clostridium scindens ATCC 35704. Biochimica et Biophysica Acta (BBA) - Mol Cell Biol Lipids. 2018;1863(3):276–283. doi:10.1016/j.bbalip.2017.12.001.
   PubMed Web of Science ®Google Scholar
• Ye L, Guo J, R-S G. Chapter thirteen - environmental pollutants and hydroxysteroid dehydrogenases. Vitam Horm. 2014;94:349–390. doi:10.1016/B978-0-12-800095-3.00013-4.
   PubMed Web of Science ®Google Scholar
• Doden HL, Ridlon JM. Microbial hydroxysteroid dehydrogenases: from alpha to omega. Microorganisms. 2021;9(3):469. doi:10.3390/microorganisms9030469.
   PubMed Web of Science ®Google Scholar
• Bennett MJ, McKnight SL, Coleman JP. Cloning and characterization of the NAD-dependent 7 alpha-hydroxysteroid dehydrogenase from Bacteroides fragilis. Curr Microbiol. 2003;47(6):475–484. doi:10.1007/s00284-003-4079-4.
   PubMed Web of Science ®Google Scholar
• Ji S, Pan Y, Zhu L, Tan J, Tang S, Yang Q, Zhang Z, Lou D, Wang B. A novel 7α-hydroxysteroid dehydrogenase: Magnesium ion significantly enhances its activity and thermostability. Int J Biol Macromol. 2021;177:111–118. doi:10.1016/j.ijbiomac.2021.02.082.
   PubMed Web of Science ®Google Scholar
• Lu Q, Jiang Z, Wang Q, Hu H, Zhao G. The effect of Tauroursodeoxycholic acid (TUDCA) and gut microbiota on murine gallbladder stone formation. Ann Hepatol. 2021;23:100289. doi:10.1016/j.aohep.2020.100289.
   PubMed Web of Science ®Google Scholar
• Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, Mai C, Jin WB, Guo CJ, Violante S. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581(7809):475–479. doi:10.1038/s41586-020-2193-0.
   PubMed Web of Science ®Google Scholar
• Paik D, Yao L, Zhang Y, Bae S, D’Agostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco J, Bisanz JE. et al. Human gut bacteria produce ΤΗ17-modulating bile acid metabolites. Nature. 2022;603(7903):907–912. doi:10.1038/s41586-022-04480-z.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou S, Wang Y, Cong J. Changes of intestinal microbiota and microbiota-based treatments in IBD. Arch Microbiol. 2022;204(7):442. doi:10.1007/s00203-022-03069-4.
   PubMed Web of Science ®Google Scholar
• Lou D, Wang B, Tan J, Zhu L. Carboxyl-terminal and Arg38 are essential for activity of the 7α-hydroxysteroid dehydrogenase from Clostridium absonum. Protein Pept Lett. 2014;21(9):894–900. doi:10.2174/0929866521666140507160050.
   PubMed Web of Science ®Google Scholar
• Edenharder R, Schneider J. 12 beta-dehydrogenation of bile acids by Clostridium paraputrificum, C. tertium, and C. difficile and epimerization at carbon-12 of deoxycholic acid by cocultivation with 12 alpha-dehydrogenating Eubacterium lentum. Appl Environ Microbiol. 1985;49(4):964–968. doi:10.1128/aem.49.4.964-968.1985.
   PubMed Web of Science ®Google Scholar
• Takei H, Narushima S, Suzuki M, Kakiyama G, Sasaki T, Murai T, Yamashiro Y, Nittono H. Characterization of long-chain fatty acid-linked bile acids: a major conjugation form of 3β-hydroxy bile acids in feces. J Lipid Res. 2022;63(10):100275. doi:10.1016/j.jlr.2022.100275.
   PubMed Web of Science ®Google Scholar
• Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20(4):461–472. doi:10.1007/s11154-019-09512-0.
   PubMed Web of Science ®Google Scholar
• Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. 2014;3(1):14–24. doi:10.3390/pathogens3010014.
   Google Scholar
• Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108(2):225–246. doi:10.1093/toxsci/kfn268.
   PubMed Web of Science ®Google Scholar
• Guzior DV, Okros M, Shivel M, Armwald B, Bridges C, Fu Y, Martin C, Schilmiller AL, Miller WM, Ziegler KM. et al. Bile salt hydrolase acyltransferase activity expands bile acid diversity. Nature. 2024;626(8000):852–858. doi:10.1038/s41586-024-07017-8.
   PubMed Web of Science ®Google Scholar
• Rimal B, Collins SL, Tanes CE, Rocha ER, Granda MA, Solanki S, Hoque NJ, Gentry EC, Koo I, Reilly ER. et al. Bile salt hydrolase catalyses formation of amine-conjugated bile acids. Nature. 2024;626(8000):859–863. doi:10.1038/s41586-023-06990-w.
   PubMed Web of Science ®Google Scholar
• Xu XW, Ocansey DKW, Hang SH, Wang B, Amoah S, Yi CX, Zhang X, Liu LQ, Mao F. The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease. Gut Pathog. 2022;14(1):26. doi:10.1186/s13099-022-00499-9.
   PubMed Web of Science ®Google Scholar
• Li N, Zhan S, Tian Z, Liu C, Xie Z, Zhang S, Chen M, Zeng Z, Zhuang X. Alterations in bile acid metabolism associated with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(9):1525–1540. doi:10.1093/ibd/izaa342.
   PubMed Web of Science ®Google Scholar
• Lenicek M, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, Vitek L. Bile acid malabsorption in inflammatory bowel disease: Assessment by serum markers. Inflamm Bowel Dis. 2011;17(6):1322–1327. doi:10.1002/ibd.21502.
   PubMed Web of Science ®Google Scholar
• Battat R, Scherl EJ, Lukin D, Charilaou P, Mahtani P, Gerber J, Gandara JA, Dündar F, Zumbo P, Betel D. et al. Increased primary bile acids with ileocolonic resection impact ileal inflammation and gut microbiota in inflammatory bowel disease. J Crohns Colitis. 2023;17(5):795–803. doi:10.1093/ecco-jcc/jjac173.
   PubMed Web of Science ®Google Scholar
• Chiang JYL. Bile acids: regulation of synthesis: thematic Review Series: Bile Acids. J Lipid Res. 2009;50(10):1955–1966. doi:10.1194/jlr.R900010-JLR200.
   PubMed Web of Science ®Google Scholar
• Das P, Marcisauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics. 2019;20(1):157. doi:10.1186/s12864-019-5899-3.
   PubMedGoogle Scholar
• Heinken A, Ravcheev DA, Baldini F, Heirendt L, Fleming RMT, Thiele I. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7(1):75. doi:10.1186/s40168-019-0689-3.
   PubMed Web of Science ®Google Scholar
• Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539. doi:10.1136/gutjnl-2012-302578.
   PubMed Web of Science ®Google Scholar
• Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–662. doi:10.1038/s41586-019-1237-9.
   PubMed Web of Science ®Google Scholar
• Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, Sim D, Jarr K, Spear ET, Singh G. et al. Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe. 2020;27(4):659–670.e5. doi:10.1016/j.chom.2020.01.021.
   PubMed Web of Science ®Google Scholar
• Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol. 2021;27(24):3609–3629. doi:10.3748/wjg.v27.i24.3609.
   PubMed Web of Science ®Google Scholar
• Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293–305. doi:10.1038/s41564-018-0306-4.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci Usa. 2007;104(34):13780–13785. doi:10.1073/pnas.0706625104.
   PubMed Web of Science ®Google Scholar
• Kruis W, Kalek HD, Stellaard F, Paumgartner G. Altered fecal bile acid pattern in patients with inflammatory bowel disease. Digestion. 1986;35(4):189–198. doi:10.1159/000199367.
   PubMed Web of Science ®Google Scholar
• Connors J, Dunn KA, Allott J, Bandsma R, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The relationship between fecal bile acids and microbiome community structure in pediatric Crohn’s disease. Isme J. 2020;14(3):702–713. doi:10.1038/s41396-019-0560-3.
   PubMed Web of Science ®Google Scholar
• Diederen K, Li JV, Donachie GE, de Meij TG, de Waart DR, Hakvoort TBM, Kindermann A, Wagner J, Auyeung V, Te Velde AA. et al. Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease. Sci Rep. 2020;10(1):18879. doi:10.1038/s41598-020-75306-z.
   PubMed Web of Science ®Google Scholar
• Murakami M, Iwamoto J, Honda A, Tsuji T, Tamamushi M, Ueda H, Monma T, Konishi N, Yara S, Hirayama T. et al. Detection of gut dysbiosis due to reduced clostridium subcluster XIVa using the fecal or serum bile acid profile. Inflamm Bowel Dis. 2018;24(5):1035–1044. doi:10.1093/ibd/izy022.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao X, Zhang X, Xiao F, Hu H, Li X, Dong F, Sun M, Xiao Y, Ge T. et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes. 2021;13(1):1865708. doi:10.1080/19490976.2020.1865708.
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Kaiser T, Staley C, Hamilton MJ, Reich J, Graiziger C, Singroy S, Kabage AJ, Sadowsky MJ, Khoruts A. A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. Clin Exp Gastroenterol. 2019;12:9–19. doi:10.2147/CEG.S186097.
   PubMed Web of Science ®Google Scholar
• Torres J, Palmela C, Brito H, Bao X, Ruiqi H, Moura-Santos P, da Silva JP, Oliveira A, Vieira C, Perez K. et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United European Gastroenterol J. 2018;6(1):112–122. doi:10.1177/2050640617708953.
   PubMed Web of Science ®Google Scholar
• Lavelle A, Nancey S, Reimund JM, Laharie D, Marteau P, Treton X, Allez M, Roblin X, Malamut G, Oeuvray C. et al. Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer. Gut Microbes. 2022;14(1):2078620. doi:10.1080/19490976.2022.2078620.
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362–1365. doi:10.1126/science.284.5418.1362.
   PubMed Web of Science ®Google Scholar
• Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol. 2013;14(7):676–684. doi:10.1038/ni.2640.
   PubMed Web of Science ®Google Scholar
• Iliev ID. Mycobiota-host immune interactions in IBD: coming out of the shadows. Nat Rev Gastro Hepat. 2022;19(2):91–92. doi:10.1038/s41575-021-00541-2.
   PubMed Web of Science ®Google Scholar
• Wilson A, Wang Q, Almousa AA, Jansen LE, Choi Y-H, Schwarz UI, Kim RB. Genetic variation in the farnesoid X-receptor predicts Crohn’s disease severity in female patients. Sci Rep. 2020;10(1):11725. doi:10.1038/s41598-020-68686-9.
   PubMed Web of Science ®Google Scholar
• Shin D-J, Wang L. Bile acid-activated receptors: a review on FXR and other nuclear receptors. Handb Exp Pharmacol. 2019;256:51–72. doi:10.1007/164_2019_236.
   PubMedGoogle Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, Klomp LWJ, Siersema PD, Schipper MEI, Danese S. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. GUT. 2011;60(4):463–472. doi:10.1136/gut.2010.212159.
   PubMed Web of Science ®Google Scholar
• Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251–6261. doi:10.4049/jimmunol.0803978.
   PubMed Web of Science ®Google Scholar
• Thibaut MM, Bindels LB. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation. Trends Mol Med. 2022;28(3):223–236. doi:10.1016/j.molmed.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, Geva-Zatorsky N, Jupp R, Mathis D, Benoist C. et al. Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis. Nature. 2020;577(7790):410–415. doi:10.1038/s41586-019-1865-0.
   PubMed Web of Science ®Google Scholar
• Massafra V, Ijssennagger N, Plantinga M, Milona A, Ramos Pittol JM, Boes M, van Mil SWC. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim Biophys Acta Mol Basis Dis. 2016;1862(2):166–173. doi:10.1016/j.bbadis.2015.11.001.
   Web of Science ®Google Scholar
• Pan X, Zhu Q, Pan LL, Sun J. Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy. Pharmacology & Therapeutics. 2022;238:108176. doi:10.1016/j.pharmthera.2022.108176.
   PubMed Web of Science ®Google Scholar
• Biagioli M, Carino A, Cipriani S, Francisci D, Marchianò S, Scarpelli P, Sorcini D, Zampella A, Fiorucci S. The bile acid receptor gpbar1 regulates the m1/m2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis. J Immunol. 2017;199(2):718–733. doi:10.4049/jimmunol.1700183.
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Perino A, Yildiz E, El Alam G, Bou Sleiman M, Gioiello A, Pellicciari R, Schoonjans K. Bile acids signal via tgr5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology. 2020;159(3):956–968.e958. doi:10.1053/j.gastro.2020.05.067.
   PubMed Web of Science ®Google Scholar
• Chen Y, Le TH, Du Q, Zhao Z, Liu Y, Zou J, Hua W, Liu C, Zhu Y. Genistein protects against DSS-induced colitis by inhibiting NLRP3 inflammasome via TGR5-cAMP signaling. Int Immunopharmacol. 2019;71:144–154. doi:10.1016/j.intimp.2019.01.021.
   PubMed Web of Science ®Google Scholar
• Guo CS, Xie SJ, Chi ZX, Zhang JH, Liu YY, Zhang L, Zheng MZ, Zhang X, Xia DJ, Ke YH. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45(4):944. doi:10.1016/j.immuni.2016.10.009.
   PubMed Web of Science ®Google Scholar
• Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L. et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature. 2019;576(7785):143–148. doi:10.1038/s41586-019-1785-z.
   PubMed Web of Science ®Google Scholar
• Lee GR. The balance of Th17 versus treg cells in autoimmunity. Int J Mol Sci. 2018;19(3):730. doi:10.3390/ijms19030730.
   PubMed Web of Science ®Google Scholar
• Sefik E, Geva-Zatorsky N, Oh S, Konnikova L, Zemmour D, McGuire AM, Burzyn D, Ortiz-Lopez A, Lobera M, Yang J. et al. Individual intestinal symbionts induce a distinct population of RORγ+ regulatory T cells. Science. 2015;349(6251):993–997. doi:10.1126/science.aaa9420.
   PubMed Web of Science ®Google Scholar
• Ishizawa M, Matsunawa M, Adachi R, Uno S, Ikeda K, Masuno H, Shimizu M, Iwasaki KI, Yamada S, Makishima M. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J Lipid Res. 2008;49(4):763–772. doi:10.1194/jlr.M700293-JLR200.
   PubMed Web of Science ®Google Scholar
• Cantorna MT, Rogers CJ, Arora J. Aligning the paradoxical role of Vitamin D in gastrointestinal immunity. Trends In Endocrinol Metabolism. 2019;30(7):459–466. doi:10.1016/j.tem.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Cheng J, Fang ZZ, Kim JH, Krausz KW, Tanaka N, Chiang JYL, Gonzalez FJ. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J Lipid Res. 2014;55(3):455–465. doi:10.1194/jlr.M044420.
   PubMed Web of Science ®Google Scholar
• Pols TWH, Puchner T, Korkmaz HI, Vos M, Soeters MR, de Vries CJM, Rottenberg ME. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. PLOS ONE. 2017;12(5):e0176715. doi:10.1371/journal.pone.0176715.
   PubMed Web of Science ®Google Scholar
• He L, Liu T, Shi Y, Tian F, Hu H, Deb DK, Chen Y, Bissonnette M, Li YC. Gut epithelial vitamin d receptor regulates microbiota-dependent mucosal inflammation by suppressing intestinal epithelial cell apoptosis. Endocrinology. 2018;159(2):967–979. doi:10.1210/en.2017-00748.
   PubMed Web of Science ®Google Scholar
• Huang K, Mukherjee S, Desmarais V, Albanese JM, Rafti E, Draghi A, Maher LA, Khanna KM, Mani S, Matson AP. Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. Pediatr Res. 2018;83(5):1031–1040. doi:10.1038/pr.2018.14.
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Renga B, Palladino G, Claudio D, Ricci P, Distrutti E, Barbanti M, Baldelli F, Fiorucci S. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol. 2011;668(1–2):317–324. doi:10.1016/j.ejphar.2011.06.058.
   PubMed Web of Science ®Google Scholar
• Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression. Am J Physiol-Gastr L. 2007;292(4):G1114–G1122. doi:10.1152/ajpgi.00528.2006.
   PubMed Web of Science ®Google Scholar
• Little M, Dutta M, Li H, Matson A, Shi X, Mascarinas G, Molla B, Weigel K, Gu H, Mani S. et al. Understanding the physiological functions of the host xenobiotic-sensing nuclear receptors PXR and CAR on the gut microbiome using genetically modified mice. Acta Pharm Sin B. 2022;12(2):801–820. doi:10.1016/j.apsb.2021.07.022.
   PubMed Web of Science ®Google Scholar
• Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, Buck GA, Snyder MP, Strauss JF, Weinstock GM. et al. The integrative human microbiome project. Nature. 2019;569(7758):641–648. doi:10.1038/s41586-019-1238-8.
   PubMed Web of Science ®Google Scholar
• He PD, Yu LL, Tian FW, Zhang H, Chen W, Zhai QX. Dietary patterns and gut microbiota: the crucial actors in inflammatory bowel disease. Adv Nutr. 2022;13(5):1628–1651. doi:10.1093/advances/nmac029.
   PubMed Web of Science ®Google Scholar
• Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017;8(2):172–184. doi:10.1080/19490976.2017.1290756.
   PubMed Web of Science ®Google Scholar
• Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563–573. doi:10.1038/ajg.2011.44.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, Lee D, Bittinger K, Bailey A, Friedman ES, Hoffmann C. et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18(4):489–500. doi:10.1016/j.chom.2015.09.008.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, Amil Dias J, Barabino A, Braegger CP, Bronsky J. et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohn’s Colitis. 2014;8(10):1179–1207. doi:10.1016/j.crohns.2014.04.005.
   Google Scholar
• Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastro Hepat. 2022;19(10):652–669. doi:10.1038/s41575-022-00619-5.
   PubMed Web of Science ®Google Scholar
• Sanderson IR, Bustin SA, Dziennis S, Paraszczuk J, Stamm DS. Age and diet act through distinct isoforms of the class II transactivator gene in mouse intestinal epithelium. Gastroenterology. 2004;127(1):203–212. doi:10.1053/j.gastro.2004.04.014.
   PubMed Web of Science ®Google Scholar
• Levine A, Wine E. Effects of enteral nutrition on Crohn’s PLOS ONEisease: Clues to the impact of diet on disease pathogenesis. Inflamm Bowel Dis. 2013;19(6):1322–1329. doi:10.1097/MIB.0b013e3182802acc.
   PubMed Web of Science ®Google Scholar
• Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008;28(6):724–733. doi:10.1111/j.1365-2036.2008.03796.x.
   PubMed Web of Science ®Google Scholar
• Ke J, Li Y, Han C, He R, Lin R, Qian W, Hou X. Fucose ameliorate intestinal inflammation through modulating the crosstalk between bile acids and gut microbiota in a chronic colitis murine model. Inflamm Bowel Dis. 2020;26(6):863–873. doi:10.1093/ibd/izaa007.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Engle A, Simi B, Goldman M. Effect of dietary fiber on colonic bacterial enzymes and bile acids in relation to colon cancer. Gastroenterology. 1992;102(5):1475–1482. doi:10.1016/0016-5085(92)91704-8.
   PubMed Web of Science ®Google Scholar
• Makki K, Brolin H, Petersen N, Henricsson M, Christensen DP, Khan MT, Wahlström A, Bergh PO, Tremaroli V, Schoonjans K. et al. 6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice. Gut. 2023;72(2):314–324. doi:10.1136/gutjnl-2021-326541.
   PubMed Web of Science ®Google Scholar
• Reuter MA, Tucker M, Marfori Z, Shishani R, Bustamante JM, Moreno R, Goodson ML, Ehrlich A, Taha AY, Lein PJ. et al. Dietary resistant starch supplementation increases gut luminal deoxycholic acid abundance in mice. Gut Microbes. 2024;16(1):2315632. doi:10.1080/19490976.2024.2315632.
   PubMed Web of Science ®Google Scholar
• Kuang R, Binion DG. Should high-fiber diets be recommended for patients with inflammatory bowel disease? Curr Opin Gastroenterol. 2022;38(2):168–172. doi:10.1097/mog.0000000000000810.
   PubMed Web of Science ®Google Scholar
• Limdi JK, Aggarwal D, McLaughlin JT. Dietary practices and beliefs in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):164–170. doi:10.1097/mib.0000000000000585.
   PubMed Web of Science ®Google Scholar
• Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable carbohydrates [FODMAPs] exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial. J Crohns Colitis. 2017;11(12):1420–1429. doi:10.1093/ecco-jcc/jjx073.
   PubMed Web of Science ®Google Scholar
• Llewellyn SR, Britton GJ, Contijoch EJ, Vennaro OH, Mortha A, Colombel JF, Grinspan A, Clemente JC, Merad M, Faith JJ. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in mice. Gastroenterology. 2018;154(4):1037–1046.e1032. doi:10.1053/j.gastro.2017.11.030.
   PubMed Web of Science ®Google Scholar
• Bretin A, Zou J, San Yeoh B, Ngo VL, Winer S, Winer DA, Reddivari L, Pellizzon M, Walters WA, Patterson AD. et al. Psyllium fiber protects against colitis via activation of bile acid sensor farnesoid x receptor. Cell Mol Gastroenterol Hepatol. 2023;15(6):1421–1442. doi:10.1016/j.jcmgh.2023.02.007.
   PubMed Web of Science ®Google Scholar
• Armstrong HK, Bording-Jorgensen M, Santer DM, Zhang Z, Valcheva R, Rieger AM, Sung-Ho Kim J, Dijk SI, Mahmood R, Ogungbola O. et al. Unfermented β-fructan fibers fuel inflammation in select inflammatory bowel disease patients. Gastroenterology. 2023;164(2):228–240. doi:10.1053/j.gastro.2022.09.034.
   PubMed Web of Science ®Google Scholar
• Bonazzi E, Bretin A, Vigué L, Hao F, Patterson AD, Gewirtz AT, Chassaing B. Individualized microbiotas dictate the impact of dietary fiber on colitis sensitivity. Microbiome. 2024;12(1):5. doi:10.1186/s40168-023-01724-6.
   PubMed Web of Science ®Google Scholar
• Jia YQ, Yuan ZW, Zhang XS, Dong JQ, Liu XN, Peng XT, Yao WL, Ji P, Wei YM, Hua YL. Total alkaloids of Sophora alopecuroides L. ameliorated murine colitis by regulating bile acid metabolism and gut microbiota. J Ethnopharmacol. 2020;255:112775. doi:10.1016/j.jep.2020.112775.
   PubMed Web of Science ®Google Scholar
• Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, Lu H, Wang S. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacol Res. 2021;171:105767. doi:10.1016/j.phrs.2021.105767.
   PubMed Web of Science ®Google Scholar
• Yu ZT, Li DG, Sun HX. Herba origani alleviated DSS-induced ulcerative colitis in mice through remolding gut microbiota to regulate bile acid and short-chain fatty acid metabolisms. Biomed Pharmacother. 2023; 161. doi:10.1016/j.biopha.2023.114409.
   Web of Science ®Google Scholar
• O’Mahony C, Amamou A, Ghosh S. Diet-microbiota interplay: an emerging player in macrophage plasticity and intestinal health. Int J Mol Sci. 2022;23(7):3901. doi:10.3390/ijms23073901.
   PubMed Web of Science ®Google Scholar
• Serrano-Moreno C, Brox-Torrecilla N, Arhip L, Romero I, Morales A, Luisa Carrascal M, Cuerda C, Motilla M, Camblor M, Velasco C. et al. Diets for inflammatory bowel disease: What do we know so far? Eur J Clin Nutr. 2022;76(9):1222–1233. doi:10.1038/s41430-021-01051-9.
   PubMed Web of Science ®Google Scholar
• Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastro Hepat. 2010;7(9):503–514. doi:10.1038/nrgastro.2010.117.
   PubMed Web of Science ®Google Scholar
• Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16(10):605–616. doi:10.1038/s41575-019-0173-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo Y, Chen H, Wei H, Wan C. Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress. Can J Microbiol. 2018;64(5):327–337. doi:10.1139/cjm-2017-0716.
   PubMed Web of Science ®Google Scholar
• Xiao F, Dong F, Li X, Li Y, Yu G, Liu Z, Wang Y, Zhang T. Bifidobacterium longum CECT 7894 improves the efficacy of infliximab for DSS-Induced colitis via regulating the gut microbiota and bile acid metabolism. Front Pharmacol. 2022;13:902337. doi:10.3389/fphar.2022.902337.
   PubMed Web of Science ®Google Scholar
• Wong WY, Chan BD, Sham TT, Lee MML, Chan CO, Chau CT, Mok DKW, Kwan YW, Tai WCS. Lactobacillus casei strain shirota ameliorates dextran sulfate sodium-induced colitis in mice by increasing taurine-conjugated bile acids and inhibiting NF-kappa B signaling via stabilization of I kappa B alpha. Front Nutr. 2022;9:816836. doi:10.3389/fnut.2022.816836.
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M. et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. GUT. 2004;53(11):1617–1623. doi:10.1136/gut.2003.037747.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA. et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–2227. doi:10.1038/ajg.2010.218.
   PubMed Web of Science ®Google Scholar
• Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437–443. doi:10.1038/ajg.2008.118.
   PubMed Web of Science ®Google Scholar
• van der Lelie D, Oka A, Taghavi S, Umeno J, Fan T-J, Merrell KE, Watson SD, Ouellette L, Liu B, Awoniyi M. et al. Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nat Commun. 2021;12(1):3105. doi:10.1038/s41467-021-23460-x.
   PubMed Web of Science ®Google Scholar
• Yadav MK, Kumari I, Singh B, Sharma KK, Tiwari SK. Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Appl Microbiol Biotechnol. 2022;106(2):505–521. doi:10.1007/s00253-021-11646-8.
   PubMed Web of Science ®Google Scholar
• Scott KP, Martin JC, Duncan SH, Flint HJ. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. FEMS Microbiol Ecol. 2014;87(1):30–40. doi:10.1111/1574-6941.12186.
   PubMed Web of Science ®Google Scholar
• Alexander C, Cross T-W, Devendran S, Neumer F, Theis S, Ridlon JM, Suchodolski JS, De Godoy MRC, Swanson KS, de Godoy MRC. Effects of prebiotic inulin-type fructans on blood metabolite and hormone concentrations and faecal microbiota and metabolites in overweight dogs. Br J Nutr. 2018;120(6):711–720. doi:10.1017/S0007114518001952.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Z, Zhu L, Dai N, Sun G, Peng L, Wang X, Yang Y. Effects of xylo-oligosaccharide on the gut microbiota of patients with ulcerative colitis in clinical remission. Front Nutr. 2021;8:778542. doi:10.3389/fnut.2021.778542.
   PubMed Web of Science ®Google Scholar
• He L, Zhang F, Jian Z, Sun J, Chen J, Liapao V, He Q. Stachyose modulates gut microbiota and alleviates dextran sulfate sodium-induced acute colitis in mice. Saudi J Gastroenterol: Off J Saudi Gastroenterol Assoc. 2020;26(3):153–159. doi:10.4103/sjg.SJG_580_19.
   PubMed Web of Science ®Google Scholar
• Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Gut Microbes. 2019;10(3):334–357. doi:10.1080/19490976.2018.1526583.
   PubMed Web of Science ®Google Scholar
• Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S. et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT national registry. Gastroenterology. 2021;160(1):183–192.e183. doi:10.1053/j.gastro.2020.09.038.
   PubMed Web of Science ®Google Scholar
• Verdier C, Denis S, Gasc C, Boucinha L, Uriot O, Delmas D, Dore J, Le Camus C, Schwintner C, Blanquet-Diot S. An oral FMT capsule as efficient as an enema for microbiota reconstruction following disruption by antibiotics, as assessed in an in vitro human gut model. Microorganisms. 2021;9(2):358. doi:10.3390/microorganisms9020358.
   PubMed Web of Science ®Google Scholar
• Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM. et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. GUT. 2019;68(10):1791–1800. doi:10.1136/gutjnl-2018-317842.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–109.e106. doi:10.1053/j.gastro.2015.04.001.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Nielsen S, Kamm MA, Deshpande NP, Faith JJ, Clemente JC, Paramsothy R, Walsh AJ, van den Bogaerde J, Samuel D. et al. Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology. 2019;156(5):1440–1454.e1442. doi:10.1053/j.gastro.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, Luu LDW, Borody TJ, Leong RW. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022;7(2):141–151. doi:10.1016/s2468-1253(21)00400-3.
   PubMed Web of Science ®Google Scholar
• Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, Bourrier A, Le Gall G, Lalande V, De Rougemont A. et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome. 2020;8(1):12. doi:10.1186/s40168-020-0792-5.
   PubMed Web of Science ®Google Scholar
• Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci. 2018;63(7):1890–1899. doi:10.1007/s10620-018-5086-4.
   PubMed Web of Science ®Google Scholar
• Keely SJ, Steer CJ, Lajczak-McGinley NK. Ursodeoxycholic acid: a promising therapeutic target for inflammatory bowel diseases? Am J Physiol Gastrointest Liver Physiol. 2019;317(6):G872–G881. doi:10.1152/ajpgi.00163.2019.
   PubMed Web of Science ®Google Scholar
• Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, Vilchez-Vargas R, Vital M, Pieper Dietmar H, Vanden Bussche J. et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microb. 2017;83(7):e02766–02716. doi:10.1128/AEM.02766-16.
   PubMed Web of Science ®Google Scholar
• He Q, Wu J, Ke J, Zhang Q, Zeng W, Luo Z, Gong J, Chen Y, He Z, Lan P. Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation. Mol Ther. 2023;31(2):585–598. doi:10.1016/j.ymthe.2022.10.014.
   PubMed Web of Science ®Google Scholar
• Pearson T, Caporaso JG, Yellowhair M, Bokulich NA, Padi M, Roe DJ, Wertheim BC, Linhart M, Martinez JA, Bilagody C. et al. Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development. Cancer Med. 2019;8(2):617–628. doi:10.1002/cam4.1965.
   PubMed Web of Science ®Google Scholar
• Van den Bossche L, Borsboom D, Devriese S, Van Welden S, Holvoet T, Devisscher L, Hindryckx P, De Vos M, Laukens D. Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens Crohn’s disease-like ileitis. Lab Invest. 2017;97(5):519–529. doi:10.1038/labinvest.2017.6.
   PubMed Web of Science ®Google Scholar
• Martínez-Moya P, Romero-Calvo I, Requena P, Hernández-Chirlaque C, Aranda CJ, González R, Zarzuelo A, Suárez MD, Martínez-Augustin O, Marín JJG. et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013;15(2):372–380. doi:10.1016/j.intimp.2012.11.017.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VAC, Harrison EM, McCashland T, Befeler AS, Harnois D. et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106(9):1638–1645. doi:10.1038/ajg.2011.156.
   PubMed Web of Science ®Google Scholar
• Jia BL, Park D, Hahn Y, Jeon CO. Metagenomic analysis of the human microbiome reveals the association between the abundance of gut bile salt hydrolases and host health. Gut Microbes. 2020;11(5):1300–1313. doi:10.1080/19490976.2020.1748261.
   PubMed Web of Science ®Google Scholar
• Parasar B, Zhou H, Xiao XY, Shi QOJ, Brito IL, Chang PV. Chemoproteomic profiling of gut microbiota-associated bile salt hydrolase activity. ACS Cent Sci. 2019;5(5):867–873. doi:10.1021/acscentsci.9b00147.
   PubMed Web of Science ®Google Scholar
• Smith K, Zeng XM, Lin J, Zhou H. Discovery of bile salt hydrolase inhibitors using an efficient high-throughput screening system. PLoS One. 2014;9(1):e85344. doi:10.1371/journal.pone.0085344.
   PubMed Web of Science ®Google Scholar
• Adhikari AA, Ramachandran D, Chaudhari SN, Powell CE, Li W, McCurry MD, Banks AS, Devlin AS. A gut-restricted lithocholic acid analog as an inhibitor of gut bacterial bile salt hydrolases. ACS Chem Biol. 2021;16(8):1401–1412. doi:10.1021/acschembio.1c00192.
   PubMed Web of Science ®Google Scholar
• Su Y, Zhu Q, Hong X, R-S G. Taxifolin inhibits neurosteroidogenic rat steroid 5α-reductase 1 and 3α-hydroxysteroid dehydrogenase. Pharmacology. 2019;105(7–8):397–404. doi:10.1159/000504057.
   PubMed Web of Science ®Google Scholar
• Binli F, İnan İ, Büyükbudak F, Gram A, Kaya D, Liman N, Aslan S, Fındık M, Ay SS. The efficacy of a 3β-hydroxysteroid dehydrogenase inhibitor for the termination of mid-term pregnancies in dogs. Animals. 2022;12(18):2475. doi:10.3390/ani12182475.
   Web of Science ®Google Scholar
• Shen H, Aggarwal N, Wun KS, Lee YS, Hwang IY, Chang MW. Engineered microbial systems for advanced drug delivery. Adv Drug Deliv Rev. 2022;187:114364. doi:10.1016/j.addr.2022.114364.
   PubMed Web of Science ®Google Scholar
• Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(6):754–759. doi:10.1016/j.cgh.2006.03.028.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E. et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010;3(1):49–56. doi:10.1038/mi.2009.116.
   PubMed Web of Science ®Google Scholar
• Praveschotinunt P, Duraj-Thatte AM, Gelfat I, Bahl F, Chou DB, Joshi NS. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut. Nat Commun. 2019;10(1):5580. doi:10.1038/s41467-019-13336-6.
   PubMedGoogle Scholar
• Gadaleta RM, Cariello M, Crudele L, Moschetta A. Bile salt hydrolase-competent probiotics in the management of IBD: Unlocking the “Bile Acid Code”. Nutrients. 2022;14(15):3212. doi:10.3390/nu14153212.
   PubMed Web of Science ®Google Scholar
• Streidl T, Karkossa I, Segura Muñoz RR, Eberl C, Zaufel A, Plagge J, Schmaltz R, Schubert K, Basic M, Schneider KM. et al. The gut bacterium Extibacter muris produces secondary bile acids and influences liver physiology in gnotobiotic mice. Gut Microbes. 2021;13(1):1–21. doi:10.1080/19490976.2020.1854008.
   PubMed Web of Science ®Google Scholar
• Kim KH, Park D, Jia B, Baek JH, Hahn Y, Jeon CO, Chu H. Identification and characterization of major bile acid 7α-dehydroxylating bacteria in the human gut. mSystems. 2022;7(4):e0045522. doi:10.1128/msystems.00455-22.
   PubMed Web of Science ®Google Scholar
• Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–208. doi:10.1038/nature13828.
   PubMed Web of Science ®Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512. doi:10.1128/jb.01765-07.
   PubMed Web of Science ®Google Scholar
• Koh E, Hwang IY, Lee HL, De Sotto R, Lee JWJ, Lee YS, March JC, Chang MW. Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism. Nat Commun. 2022;13(1):3834. doi:10.1038/s41467-022-31334-z.
   PubMed Web of Science ®Google Scholar